Markets:

Overview

News

Currencies

International

Treasuries

Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.87 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intra-Cellular Therapies Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...

Via MarketMinute

Why Mark Minervini may look into INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) ↗

April 08, 2025

A fundamental and technical analysis of (NASDAQ:ITCI): Why INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) qualifies as a high growth stock.

Via Chartmill

Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews ↗

April 02, 2025

Via Benzinga

Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended ↗

April 02, 2025

Shares of Johnson & Johnson (JNJ) sold off on news regarding a dilution of its earnings. The selloff ended when it reach support.

Via Benzinga

Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

February 21, 2025

Via Benzinga

Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews ↗

January 22, 2025

Via Benzinga

Evaluating INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) using Mark Minervini’s winning stock formula ↗

March 18, 2025

A fundamental and technical analysis of (NASDAQ:ITCI): Should you consider INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) for high growth investing?

Via Chartmill

Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy' ↗

March 07, 2025

Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion

Via Benzinga

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

February 25, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders

February 24, 2025

From Halper Sadeh LLC

Via Business Wire

Nike To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Monday ↗

February 24, 2025

Via Benzinga

This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

February 24, 2025

Via Benzinga

Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst ↗

February 18, 2025

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Via Benzinga

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LGTY, ENFN, ITCI, SSTK on Behalf of Shareholders

February 04, 2025

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)

February 04, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

January 27, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook ↗

January 22, 2025

Johnson & Johnson's Q4 sales hit $22.52 billion, with strong growth in MedTech and oncology. 2025 guidance shows promising EPS and revenue forecasts.

Via Benzinga

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, HEES, SSTK on Behalf of Shareholders

January 21, 2025

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), H&E Equipment Services, Inc. (Nasdaq - HEES), Shutterstock, Inc. (NYSE - SSTK)

January 21, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Top 4 Health Care Stocks You May Want To Dump In Q1 ↗

January 21, 2025

Via Benzinga

MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? ↗

January 19, 2025

These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, MicroStrategy, and United Rentals.

Via Benzinga

MarketBeat Week in Review – 01/13 - 01/17

January 18, 2025

The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally

Via MarketBeat

Topics Economy Energy

Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗

January 17, 2025

Many stocks flashed buy signals as the major indexes rose to or above key levels.

Via Investor's Business Daily

Topics Economy

Is Johnson & Johnson Stock Set to Reward Long-Term Holders?

January 17, 2025

JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive

Via MarketBeat

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, EDBL on Behalf of Shareholders

January 13, 2025

From Halper Sadeh LLC

Via GlobeNewswire

January 13, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders

January 13, 2025

From Ademi LLP

Via Business Wire

Intra-Cellular Therapies Stock Is Surging Monday: What's Going On? ↗

January 13, 2025

Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company.

Via Benzinga

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge ↗

January 13, 2025

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Paycor HCM, Inc. (Nasdaq - PYCR), Accolade, Inc. (Nasdaq - ACCD)

January 13, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.